In 2016, PSOGI created a new classification system for PMP, which they call the “PSOGI classification”. The original classification was able to group PMPs into various groups according to their histological grade very effectively. In this new research, Dr Alvaro Arjona and colleagues from both EuroPMP and PSOGI were able to further improve on this model through the addition of the analysis of Ki67, a large nuclear protein that is often used to assess tumor cell proliferation, in high grade disease. Their research showed that there are two distinct sub-groups in the high-grade disease group, indicating that the monitoring of Ki67 could assist in tracking the disease’s progression in patients with active disease.
You can read Dr Arjona’s new paper here.